Applicant, as named in the Orange Book
Gilead
Next listed expiry: Letairis on 14 Oct 2031. 1 products with live protection, 4 without.
Products with listed protection
| Drug | Ingredient | NDA | Earliest generic entry | Basis |
|---|
| Letairis · 2 strengths ambrisentan | ambrisentan | 022081 | 14 Oct 2031 | patent, carve-out possible |
Recent events
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products without listed protection (4)
| Drug | Ingredient | NDA | Earliest generic entry | Basis |
|---|
| Cayston aztreonam | aztreonam | 050814 | open now | no listed protection |
| Emtriva emtricitabine | emtricitabine | 021500 | open now | no listed protection |
| Emtriva emtricitabine | emtricitabine | 021896 | open now | no listed protection |
| Truvada · 4 strengths emtricitabine; tenofovir disoproxil fumarate | emtricitabine; tenofovir disoproxil fumarate | 021752 | open now | no listed protection |